Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S36-S44 , March 2004

A Cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension

  • John G. Walt, MBA

      Affiliations

    • Corresponding Author InformationReprint address: John Walt, MBA, Global Pharmacoeconomic Strategy and Research, Allergan Inc, 2525 Dupont Drive, Irvine, CA, 92612-1599.
    • ,
  • Jeffrey T. Lee, PharmD, FCCP

References 

  1. The AGIS Investigators . The advanced glaucoma intervention study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440
  2. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 1996;103:1916–1924
  3. DuBiner H, Cooke D, Dirks M. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45(Suppl 4):S353–S360
  4. Gandolfi S, Simmons ST, Sturm R. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110–121
  5. Higginbotham EJ, Schuman JS, Goldberg I. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286–1293
  6. Kass MA, Heuer DK, Higginbotham EJ. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713 discussion 829–30
  7. Kobelt G. Health Economics: An Introduction to Economic Evaluation. London: Office of Health Economics; 2002;
  8. Leske MC, Heijl A, Hussein M. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48–56
  9. Mick AB, Gonzalez S, Dunbar MT, McSoley JJ. A Cost analysis of the prostaglandin analogs. Optometry. 2002;73:614–619
  10. Noecker RS, Dirks MS, Choplin NT. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55–63
  11. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688–703
  12. Physicians Fee & Coding Guide. Augusta, GA: MAG Mutual HealthCare Consultants; 2003;
  13. PriceAlert, The Official Guide to Average Wholesale Pricing. Indianapolis: Facts & Comparisons; 2003;
  14. Rittenhouse B. Uses of models in economic evaluations of medicines and other health technologies. London: Office of Health Economics; 1996;
  15. Serle J, Cantor L, Gross R. Best practice treatment algorithm for primary open-angle glaucoma: implications for U.S. ophthalmology practice. Manag Care Interface. 2002;15:37–48
  16. Strutton DR, Walt JG: Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma (in press)

☆ These data were presented at the Annual Meeting of Managed Care Pharmacy; October 17–20, 2001; Dallas, TX. John Walt and Jeffrey Lee are employees of Allergan, Inc.

PII: S0039-6257(03)00193-0

doi: 10.1016/j.survophthal.2003.12.018

Survey of Ophthalmology
Volume 49, Issue 2, Supplement 1 , Pages S36-S44 , March 2004

Article Tools

* Image Usage & Resolution